De Block, Christophe http://orcid.org/0000-0002-0679-3203
Cheng, Alice Y. Y.
Anil, Gayathri
D’Cruz, John M.
Ginovker, Anna
Funding for this research was provided by:
Novo Nordisk A/S
Article History
Received: 26 January 2024
Accepted: 1 May 2024
First Online: 11 June 2024
Declarations
:
: Christophe De Block has participated in advisory boards for Abbott Diagnostics, A. Menarini Diagnostics, Insulet, Roche Diagnostics, Eli Lilly and Company, Novo Nordisk, and Novartis; has received search support from AstraZeneca, Boehringer Ingelheim, Indigo NV, and Novo Nordisk; and declares participation in speaker bureaus for Eli Lilly and Company, Novo Nordisk, A. Menarini Diagnostics, Abbott Diagnostics, and Insulet. Alice YY Cheng has received honoraria for consulting and/or speaking from Abbott, Amgen, AstraZeneca, Bayer, Bausch, Boehringer Ingelheim, Eisai, Eli Lilly, GSK, HLS Therapeutics, Insulet, Janssen, Medtronic, Novo Nordisk, Pfizer, Sanofi, and Takeda. Gayathri Anil and John Michael D'Cruz are employees of Novo Nordisk Service Centre India Private Limited. Anna Ginovker is a former employee of The Harris Poll, Princeton, NJ, USA (affiliation at the time of the study) and a current employee of Atomik Research, Bentonville, AR, USA.
: Participants provided consent to participate in the study and confidentiality was maintained with appropriate measures at all stages of the research. This study adhered to the European Pharmaceutical Market Research Association Code of Conduct 2019, page 15, Sect. 1.3, meaning it did not require Clinical Research Ethics Committee or Independent/Institutional Review Board approval for its conduct in the following countries: Brazil, Canada, Denmark, Finland, France, Germany, Greece, Italy, Japan, Mexico, the Netherlands, Norway, Poland, Russia, South Korea, Spain, Sweden, Turkey, the UK, and the USA [].